fashion -WSS

fashion

author：explore 2025-10-02 21:04:29 - browse：4

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： FTX founder Sam Bankman

focus

WSS

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

More regulation could be coming for drug ads

Astronauts get first look at the spacecraft that will fly them around the moon

Former Pear Therapeutics executives start new VC firm

knowledge

fashion

focus

In age of alternative facts, a scholarly course on calling out crap

Wegovy cuts risk of cardiovascular events by 20%, study finds

BioMarin wins approval for gene therapy to treat hemophilia A

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

ChatGPT in medicine: STAT answers readers' burning questions

Germany receives 178 compensation applications from gay servicepeople over discrimination

The cancer drug shortage isn’t new — and neither are the solutions

How the drug

Jerome Adams on the need for new antivirals for Covid

Former Pear Therapeutics executives start new VC firm

focus

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Wegovy cuts risk of cardiovascular events by 20%, study finds

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Former Georgia lieutenant governor says he received grand jury subpoena

More regulation could be coming for drug ads

Ohioans vote in high

entertainment

focus

focus

explore